Abstract:OBJECTIVE:To study the expression of Notch1, Jagged1 and Notch intracellular domain (NICD)in epithelial ovarian carcinoma tissues and analyze the clinical significance. To explore the activity of γ-secretase in epithelial ovarian carcinoma cell line SKOV3 and the effect of N-[N-(3, 5-dil uorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), a γ-secretase inhibitor on the activity of γ-secretase in SKOV3. METHODS:Immunohistochemistry staining method was performed in 43 patients with epithelial ovarian carcinoma and 11 patients with benign epithelial ovarian tumor to detect the expression of Notch1, Jagged1 and NICD. The differences of expressionof Notch1, Jagged1 and NICD between malignant and benign ovarian tumors was compared and alsoanalyzed the correlation with clinicopathological parameters of ovarian carcinoma. Human serous ovarian cancer cell line SKOV3 and immortalized nontumorigenic ovarian epithelial cell line T29 were incubated in vitro. The activities of γ-secretase in SKOV3 and T29 with dimethyl sulfoxide (DMSO) and DAPT were detected respectively by Gal4-VP16/UAS and dual luciferase reporter assay system. RESULTS:(1) The immunohistochemical composite scores (ICS) of Notch1 in epithelial ovarian carcinoma (6.7 ± 2.2) were not significantly different with those in benign epithelial ovarian tumor (5.4 ± 2.7, P = 0.153), while the ICS of Jagged1 and NICD in epithelial ovarian carcinoma (5.3 ± 2.4, 5.3 ± 2.3)were higher than those in benign epithelial ovarian tumor (1.6 ± 1.4, 3.1 ± 1.7; all P < 0.01). The expression of Notch1, Jagged1 and NICD had no correlation with patients' aged, history of carcinoma, ascites, the level of serum CA125, maximum length of ovarian tumor, Federation International of Gynecology and Obstetrics (FIGO) stage, grade and pathology subtypes (all P > 0.05). The hazard ratio between the high expression of Notch1, Jagged1, or NICD and the moderate to low expression of Notch1, Jagged1, or NICD, and Jagged1 were 0.771, 1.648 and 1.316, respectively (all P > 0.05). The 5-year survival rate and median survival time between the high expression of Notch, Jagged1 or NICD in subgroup and moderate to low expression in subgroup were of no difference (all P > 0.05). The activity of γ-secretase in SKOV3 was significantly higher than that in T29([ 12.2 ± 1.4)%, P = 0.019]. (2) After DAPT treated, the relative activity of γ-secretase in SKOV3 (50 µmol/L) was declined from (100.0 ± 5.3)% to(6.6 ± 0.8)% (P = 0.001). CONCLUSIONS:Jagged1 and NICD in Notch1 pathway may play a key role in the occurrence of ovarian carcinoma. The activity of γ-secretase in epithelial ovarian carcinoma was higher than that in ovarian epithelial cell which suggest that DAPT, γ-secretase inhibitor, may become the target of ovarian carcinoma treatment.

Clinicopathological and biological significance of aberrant activation of glycogen synthase kinase-3 in ovarian cancer.

Overexpression of Glycogen Synthase Kinase-3 in Ovarian Carcinoma Cells with Acquired Paclitaxel Resistance

Effects of Dynein Light Chain Tctex-type 3 on the Biological Behavior of Ovarian Cancer

Role of Glycogen Synthase Kinase-3&Amp;beta; Inhibitor AZD1080 in Ovarian Cancer

Expression of Notch1, Jagged1 and NICD in Epithelial Ovarian Carcinomas and a Preliminary Study on the Activity of Gamma-Secretase in Epithelial Ovarian Carcinoma Cell Lines

The Role of Glycogen Synthase Kinase-3Β (Gsk-3Β) in Endometrial Carcinoma: A Carcinogenesis, Progression, Prognosis, and Target Therapy Marker

Expression of pGSK-3α/β (Tyr279/216) and XIAP proteins in cholangiocarcinoma and their clinical significance

GSK3β Overexpression Indicates Poor Prognosis and Its Inhibition Reduces Cell Proliferation and Survival of Non-Small Cell Lung Cancer Cells

Effect of GSK-3β on Proliferation and Invasion of Endometrioid Adenocarcinoma

Glycogen Synthase Kinase 3 Beta In Tumorigenesis And Oncotherapy

Protective properties of glycogen synthase kinase-3 inhibition against doxorubicin-induced oxidative damage to mouse ovarian reserve.

GSK3B inhibition reduced cervical cancer cell proliferation and migration by modulating the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition

Suppression of Glycogen Synthase Kinase 3 Activity Reduces Tumor Growth of Prostate Cancer in Vivo.

ShenLingLan Influences the Attachment and Migration of Ovarian Cancer Cells Potentially Through the GSK3 Pathway

The Overexpression of Acyl-CoA Medium-Chain Synthetase-3 (ACSM3) Suppresses the Ovarian Cancer Progression Via the Inhibition of Integrin Β1/akt Signaling Pathway

Constitutive activation of glycogen synthase kinase-3beta correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer

Role of GSK-3β Activation in Responses of Colorectal Cancer Cells to EGFR and IGFR-1 Inhibitor

[Growth Inhibitory Effects of Beclin1 Gene on Epithelial Ovarian Cancer SKOV3 Cells].

Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment

MAP3K3 Overexpression is Associated with Poor Survival in Ovarian Carcinoma

Tripartite-motif 3 represses ovarian cancer progression by downregulating lactate dehydrogenase A and inhibiting AKT signaling